85
Views
1
CrossRef citations to date
0
Altmetric
Short Report

Pre-S Deletions are Predominant Quasispecies in HIV/HBV Infection: Quasispecies Perspective

ORCID Icon, , , &
Pages 1643-1649 | Published online: 08 Jun 2020

References

  • Kourtis AP, Bulterys M, Hu DJ, et al. HIV-HBV coinfection–a global challenge. N Engl J Med. 2012;366(19):1749–1752. doi:10.1056/NEJMp120179622571198
  • Zhang F, Zhu H, Wu Y, et al. HIV, hepatitis B virus, and hepatitis C virus co-infection in patients in the China national free antiretroviral treatment program, 2010–12: a retrospective observational cohort study. Lancet Infect. Dis. 2014;14(11):1065–1072. doi:10.1016/S1473-3099(14)70946-625303841
  • Tanday S. HBV and HCV co-infection increases cancer risk in HIV patients. Lancet Oncol. 2016;17(11):e484. doi:10.1016/S1470-2045(16)30512-527773486
  • Lian M, Zhou X, Chen B, et al. Identification of the critical regions in hepatitis B virus preS required for its stability. J Pept Sci. 2008;14(3):307–312. doi:10.1002/psc.92917918766
  • Yeung P, Wong DK, Lai CL, et al. Association of hepatitis B virus pre-S deletions with the development of hepatocellular carcinoma in chronic hepatitis B. J Infect Dis. 2011;203(5):646–654. doi:10.1093/infdis/jiq09621227916
  • Yeung P, Wong DK, Lai CL, et al. Profile of pre-S deletions in the natural history of chronic hepatitis B infection. J Med Virol. 2010;82(11):1843–1849. doi:10.1002/jmv.2190120872710
  • Liu F, Chen L, Yu DM, et al. Evolutionary patterns of hepatitis B virus quasispecies under different selective pressures: correlation with antiviral efficacy. Gut. 2011;60(9):1269–1277. doi:10.1136/gut.2010.22622521292683
  • Shen T. Hepatitis B virus genetic mutations and evolution in liver diseases. World J Gastroenterol. 2014;20(18):5435–5441. doi:10.3748/wjg.v20.i18.543524833874
  • Chen BF, Liu CJ, Jow GM, et al. High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases. Gastroenterology. 2006;130(4):1153–1168. doi:10.1053/j.gastro.2006.01.01116618410
  • Thio CL, Seaberg EC, Skolasky RJ, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet. 2002;360(9349):1921–1926. doi:10.1016/S0140-6736(02)11913-112493258
  • Audsley J, Littlejohn M, Yuen L, et al. HBV mutations in untreated HIV-HBV co-infection using genomic length sequencing. Virology. 2010;405(2):539–547. doi:10.1016/j.virol.2010.06.03820655563
  • Li KW, Kramvis A, Liang S, et al. Higher prevalence of cancer related mutations 1762T/1764A and PreS deletions in hepatitis B virus (HBV) isolated from HBV/HIV co-infected compared to HBV-mono-infected Chinese adults. Virus Res. 2017;227:88–95. doi:10.1016/j.virusres.2016.10.00227720823
  • Revill PA, Littlejohn M, Ayres A, et al. Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals. Aids. 2007;21(13):1701–1710. doi:10.1097/QAD.0b013e32826fb30517690567
  • Warner N, Locarnini S. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology. 2008;48(1):88–98. doi:10.1002/hep.2229518537180
  • Mondal RK, Khatun M, Ghosh S, et al. Immune-driven adaptation of hepatitis B virus genotype D involves preferential alteration in B-cell epitopes and replicative attenuation–an insight from human immunodeficiency virus/hepatitis B virus coinfection. Clin Microbiol Infect. 2015;21(7):710–711. doi:10.1016/j.cmi.2015.03.004
  • Cassino L, Laufer N, Salomon H, et al. Hepatitis B precore/core promoter mutations in isolates from HBV-monoinfected and HBV-HIV coinfected patients: a 3-yr prospective study. J Clin Virol. 2009;46(4):354–359. doi:10.1016/j.jcv.2009.09.01519800842
  • Wu CC, Chen YS, Cao L, et al. Hepatitis B virus infection: defective surface antigen expression and pathogenesis. World J Gastroenterol. 2018;24(31):3488–3499. doi:10.3748/wjg.v24.i31.348830131655
  • Hsieh YH, Su IJ, Wang HC, et al. Pre-S mutant surface antigens in chronic hepatitis B virus infection induce oxidative stress and DNA damage. Carcinogenesis. 2004;25(10):2023–2032. doi:10.1093/carcin/bgh20715180947
  • Teng YC, Neo JC, Wu JC, et al. Expression of a hepatitis B virus pre-S2 deletion mutant in the liver results in hepatomegaly and hepatocellular carcinoma in mice. J Pathol. 2017;241(4):463–474. doi:10.1002/path.485027868197
  • Ni Y, Sonnabend J, Seitz S, et al. The pre-s2 domain of the hepatitis B virus is dispensable for infectivity but serves a spacer function for L-protein-connected virus assembly. J Virol. 2010;84(8):3879–3888. doi:10.1128/JVI.02528-0920130049
  • Mun HS, Lee SA, Kim H, et al. Novel F141L pre-S2 mutation in hepatitis B virus increases the risk of hepatocellular carcinoma in patients with chronic genotype C infections. J Virol. 2011;85(1):123–132. doi:10.1128/JVI.01524-1020962085
  • Wang HC, Huang W, Lai MD, et al. Hepatitis B virus pre-S mutants, endoplasmic reticulum stress and hepatocarcinogenesis. Cancer Sci. 2006;97(8):683–688. doi:10.1111/j.1349-7006.2006.00235.x16863502
  • Desmond CP, Bartholomeusz A, Gaudieri S, et al. A systematic review of T-cell epitopes in hepatitis B virus: identification, genotypic variation and relevance to antiviral therapeutics. Antivir Ther. 2008;13(2):161–175.18505168